 Jose Banchs
Concepts (264)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Echocardiography | 16 | 2021 | 634 | 3.350 |
Why?
| | Heart Diseases | 13 | 2024 | 352 | 2.410 |
Why?
| | Neoplasms | 23 | 2024 | 2455 | 2.180 |
Why?
| | Echocardiography, Transesophageal | 5 | 2019 | 92 | 1.220 |
Why?
| | Ventricular Dysfunction, Left | 7 | 2022 | 385 | 1.160 |
Why?
| | Anthracyclines | 6 | 2024 | 49 | 1.150 |
Why?
| | Heart Ventricles | 7 | 2023 | 781 | 1.130 |
Why?
| | Ventricular Function, Left | 7 | 2022 | 528 | 1.120 |
Why?
| | Heart Neoplasms | 3 | 2018 | 50 | 0.950 |
Why?
| | Cardiovascular Diseases | 8 | 2022 | 2006 | 0.930 |
Why?
| | Antineoplastic Agents | 10 | 2019 | 2046 | 0.920 |
Why?
| | Atrial Flutter | 1 | 2023 | 35 | 0.820 |
Why?
| | Atrial Fibrillation | 3 | 2023 | 376 | 0.780 |
Why?
| | Cardiovascular System | 2 | 2023 | 136 | 0.780 |
Why?
| | Cardiotoxicity | 9 | 2024 | 33 | 0.750 |
Why?
| | Stroke Volume | 7 | 2022 | 592 | 0.730 |
Why?
| | Cardiology | 4 | 2020 | 266 | 0.730 |
Why?
| | Sarcoma | 3 | 2023 | 176 | 0.700 |
Why?
| | Medical Oncology | 5 | 2020 | 269 | 0.680 |
Why?
| | Heart Function Tests | 2 | 2019 | 59 | 0.650 |
Why?
| | Practice Patterns, Nurses' | 1 | 2018 | 19 | 0.600 |
Why?
| | Osteosarcoma | 1 | 2019 | 70 | 0.590 |
Why?
| | Thrombosis | 2 | 2018 | 348 | 0.570 |
Why?
| | Endocarditis | 2 | 2021 | 38 | 0.560 |
Why?
| | Thrombocytopenia | 1 | 2019 | 186 | 0.550 |
Why?
| | Tachycardia, Sinus | 1 | 2016 | 2 | 0.540 |
Why?
| | Diagnostic Imaging | 3 | 2018 | 325 | 0.530 |
Why?
| | Pericardial Effusion | 4 | 2019 | 21 | 0.520 |
Why?
| | Echocardiography, Three-Dimensional | 2 | 2018 | 48 | 0.500 |
Why?
| | Education, Medical, Continuing | 1 | 2016 | 122 | 0.490 |
Why?
| | Cardiomyopathies | 2 | 2016 | 340 | 0.480 |
Why?
| | Recovery of Function | 2 | 2016 | 642 | 0.480 |
Why?
| | Takotsubo Cardiomyopathy | 1 | 2015 | 3 | 0.470 |
Why?
| | Pericarditis | 1 | 2014 | 11 | 0.470 |
Why?
| | Fibroma | 1 | 2014 | 22 | 0.450 |
Why?
| | Rural Population | 1 | 2018 | 516 | 0.450 |
Why?
| | Heart | 4 | 2023 | 641 | 0.450 |
Why?
| | Aortic Aneurysm | 1 | 2014 | 65 | 0.440 |
Why?
| | Radiotherapy | 1 | 2015 | 185 | 0.440 |
Why?
| | Radiation Injuries | 1 | 2015 | 135 | 0.430 |
Why?
| | Breast Neoplasms | 7 | 2022 | 2133 | 0.410 |
Why?
| | Humans | 62 | 2024 | 129625 | 0.400 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2014 | 177 | 0.390 |
Why?
| | Multimodal Imaging | 4 | 2018 | 110 | 0.390 |
Why?
| | Cardiovascular Infections | 1 | 2012 | 2 | 0.390 |
Why?
| | Vascular Diseases | 1 | 2015 | 240 | 0.380 |
Why?
| | Tongue Neoplasms | 1 | 2012 | 24 | 0.380 |
Why?
| | Cardiac Tamponade | 3 | 2016 | 14 | 0.370 |
Why?
| | Myocarditis | 1 | 2012 | 98 | 0.360 |
Why?
| | Tracheoesophageal Fistula | 1 | 2011 | 33 | 0.360 |
Why?
| | Fluoroscopy | 1 | 2011 | 157 | 0.350 |
Why?
| | Radiography, Interventional | 1 | 2011 | 105 | 0.350 |
Why?
| | Ultrasonography, Interventional | 1 | 2011 | 128 | 0.350 |
Why?
| | Mass Screening | 1 | 2018 | 1190 | 0.340 |
Why?
| | Middle Aged | 24 | 2022 | 31136 | 0.330 |
Why?
| | Trastuzumab | 5 | 2016 | 100 | 0.320 |
Why?
| | Female | 33 | 2024 | 68734 | 0.310 |
Why?
| | Male | 29 | 2024 | 63670 | 0.300 |
Why?
| | Quality Improvement | 1 | 2016 | 1101 | 0.300 |
Why?
| | Echocardiography, Doppler, Color | 3 | 2015 | 39 | 0.290 |
Why?
| | Stents | 1 | 2011 | 504 | 0.280 |
Why?
| | Early Diagnosis | 3 | 2018 | 233 | 0.280 |
Why?
| | Coronary Artery Disease | 3 | 2021 | 679 | 0.270 |
Why?
| | Heart Failure | 4 | 2023 | 2133 | 0.260 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2012 | 627 | 0.260 |
Why?
| | Risk Factors | 12 | 2024 | 9786 | 0.250 |
Why?
| | Prognosis | 8 | 2023 | 3774 | 0.240 |
Why?
| | Heart Conduction System | 2 | 2015 | 95 | 0.230 |
Why?
| | Troponin I | 3 | 2015 | 75 | 0.230 |
Why?
| | Predictive Value of Tests | 8 | 2022 | 1947 | 0.220 |
Why?
| | Esophageal Neoplasms | 2 | 2020 | 297 | 0.220 |
Why?
| | Circulating MicroRNA | 1 | 2023 | 25 | 0.210 |
Why?
| | Lung Neoplasms | 4 | 2020 | 2342 | 0.210 |
Why?
| | Retrospective Studies | 14 | 2022 | 14522 | 0.200 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2019 | 1560 | 0.200 |
Why?
| | Fatal Outcome | 2 | 2015 | 300 | 0.200 |
Why?
| | Texas | 4 | 2021 | 237 | 0.200 |
Why?
| | Electrocardiography | 2 | 2015 | 611 | 0.190 |
Why?
| | Mitogen-Activated Protein Kinase 7 | 1 | 2021 | 21 | 0.190 |
Why?
| | Adult | 16 | 2024 | 35599 | 0.190 |
Why?
| | Ultrasonography | 3 | 2015 | 712 | 0.180 |
Why?
| | Biomarkers | 7 | 2023 | 3968 | 0.180 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2021 | 94 | 0.180 |
Why?
| | Catheters, Indwelling | 1 | 2021 | 80 | 0.180 |
Why?
| | Doxorubicin | 3 | 2023 | 329 | 0.180 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 114 | 0.180 |
Why?
| | Radiation, Ionizing | 1 | 2020 | 76 | 0.170 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2023 | 231 | 0.170 |
Why?
| | Aged | 13 | 2022 | 22061 | 0.170 |
Why?
| | Cancer Survivors | 1 | 2024 | 257 | 0.160 |
Why?
| | Graft vs Host Disease | 1 | 2021 | 240 | 0.160 |
Why?
| | ROC Curve | 2 | 2021 | 503 | 0.160 |
Why?
| | Shock, Septic | 1 | 2021 | 209 | 0.160 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2020 | 129 | 0.160 |
Why?
| | Pericardiocentesis | 1 | 2019 | 10 | 0.160 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 1049 | 0.160 |
Why?
| | Erdheim-Chester Disease | 1 | 2018 | 5 | 0.160 |
Why?
| | Systole | 2 | 2016 | 191 | 0.150 |
Why?
| | Antibiotics, Antineoplastic | 3 | 2024 | 123 | 0.150 |
Why?
| | Cardiac Imaging Techniques | 1 | 2018 | 20 | 0.150 |
Why?
| | Myxoma | 1 | 2018 | 12 | 0.150 |
Why?
| | Follow-Up Studies | 5 | 2021 | 4894 | 0.150 |
Why?
| | Carcinoid Heart Disease | 1 | 2017 | 2 | 0.140 |
Why?
| | Echocardiography, Doppler | 1 | 2018 | 108 | 0.140 |
Why?
| | Reproducibility of Results | 3 | 2016 | 3080 | 0.140 |
Why?
| | Staphylococcus aureus | 1 | 2021 | 434 | 0.140 |
Why?
| | MicroRNAs | 1 | 2023 | 679 | 0.130 |
Why?
| | Multiple Myeloma | 1 | 2018 | 125 | 0.130 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 181 | 0.130 |
Why?
| | Staphylococcal Infections | 1 | 2021 | 389 | 0.130 |
Why?
| | Oligopeptides | 1 | 2018 | 258 | 0.130 |
Why?
| | Academies and Institutes | 1 | 2016 | 50 | 0.130 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 576 | 0.130 |
Why?
| | Pericarditis, Constrictive | 1 | 2016 | 3 | 0.130 |
Why?
| | Myocardial Ischemia | 1 | 2018 | 259 | 0.130 |
Why?
| | Cardiotoxins | 1 | 2015 | 4 | 0.120 |
Why?
| | Genetic Predisposition to Disease | 1 | 2024 | 2274 | 0.120 |
Why?
| | Withholding Treatment | 1 | 2016 | 71 | 0.120 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 301 | 0.120 |
Why?
| | Cardiotonic Agents | 1 | 2016 | 126 | 0.120 |
Why?
| | Sepsis | 1 | 2021 | 575 | 0.120 |
Why?
| | Thrombolytic Therapy | 1 | 2016 | 137 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2015 | 757 | 0.120 |
Why?
| | Ventricular Dysfunction | 1 | 2015 | 15 | 0.120 |
Why?
| | Pulmonary Surgical Procedures | 1 | 2014 | 8 | 0.120 |
Why?
| | Daptomycin | 1 | 2014 | 18 | 0.120 |
Why?
| | Cefazolin | 1 | 2014 | 18 | 0.120 |
Why?
| | Pericardium | 1 | 2015 | 54 | 0.110 |
Why?
| | Comorbidity | 3 | 2019 | 1547 | 0.110 |
Why?
| | Carotid Artery Diseases | 1 | 2015 | 64 | 0.110 |
Why?
| | Dexmedetomidine | 1 | 2014 | 43 | 0.110 |
Why?
| | Preoperative Care | 2 | 2015 | 338 | 0.110 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2015 | 377 | 0.110 |
Why?
| | Pulmonary Embolism | 1 | 2016 | 212 | 0.110 |
Why?
| | Amyloidosis | 1 | 2014 | 42 | 0.110 |
Why?
| | Young Adult | 4 | 2024 | 12455 | 0.110 |
Why?
| | Survival Rate | 4 | 2021 | 1872 | 0.110 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2016 | 233 | 0.110 |
Why?
| | Heart Valve Prosthesis | 1 | 2014 | 112 | 0.100 |
Why?
| | Peroxidase | 1 | 2013 | 175 | 0.100 |
Why?
| | Postoperative Complications | 2 | 2015 | 2477 | 0.100 |
Why?
| | Myocardium | 1 | 2018 | 980 | 0.100 |
Why?
| | Chemoradiotherapy | 1 | 2014 | 208 | 0.100 |
Why?
| | Hodgkin Disease | 1 | 2015 | 134 | 0.100 |
Why?
| | Coronary Vessels | 1 | 2015 | 239 | 0.100 |
Why?
| | Radiopharmaceuticals | 1 | 2013 | 168 | 0.100 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2013 | 128 | 0.100 |
Why?
| | Heart Arrest | 1 | 2016 | 320 | 0.100 |
Why?
| | Decision Trees | 1 | 2012 | 90 | 0.100 |
Why?
| | Incidence | 4 | 2021 | 2641 | 0.100 |
Why?
| | Positron-Emission Tomography | 1 | 2013 | 282 | 0.090 |
Why?
| | Antibiotic Prophylaxis | 1 | 2012 | 101 | 0.090 |
Why?
| | Aortic Valve | 1 | 2014 | 347 | 0.090 |
Why?
| | Endocarditis, Bacterial | 1 | 2012 | 42 | 0.090 |
Why?
| | Hypertension, Pulmonary | 1 | 2023 | 1894 | 0.090 |
Why?
| | Cardiac Catheterization | 1 | 2015 | 520 | 0.090 |
Why?
| | Radiosurgery | 1 | 2013 | 321 | 0.090 |
Why?
| | Prosthesis Implantation | 1 | 2011 | 146 | 0.080 |
Why?
| | Risk Assessment | 3 | 2018 | 3262 | 0.080 |
Why?
| | Combined Modality Therapy | 3 | 2018 | 1203 | 0.080 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 482 | 0.080 |
Why?
| | Sensitivity and Specificity | 2 | 2011 | 1843 | 0.070 |
Why?
| | Aged, 80 and over | 4 | 2015 | 7052 | 0.070 |
Why?
| | Myocardial Infarction | 1 | 2015 | 1021 | 0.070 |
Why?
| | Treatment Outcome | 4 | 2018 | 10219 | 0.070 |
Why?
| | Animals | 5 | 2023 | 35391 | 0.070 |
Why?
| | Antiviral Agents | 1 | 2012 | 715 | 0.070 |
Why?
| | Adolescent | 3 | 2024 | 20412 | 0.060 |
Why?
| | Palliative Care | 1 | 2012 | 702 | 0.060 |
Why?
| | Prevalence | 1 | 2011 | 2564 | 0.060 |
Why?
| | Troponin | 1 | 2023 | 50 | 0.050 |
Why?
| | Natriuretic Peptide, Brain | 2 | 2015 | 99 | 0.050 |
Why?
| | Taxoids | 2 | 2013 | 98 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2012 | 1705 | 0.050 |
Why?
| | Ribose | 1 | 2021 | 22 | 0.050 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2022 | 77 | 0.050 |
Why?
| | Antigens, CD19 | 1 | 2022 | 120 | 0.050 |
Why?
| | Adenosine Diphosphate | 1 | 2021 | 80 | 0.050 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2021 | 42 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2021 | 234 | 0.050 |
Why?
| | Mitral Valve Insufficiency | 1 | 2001 | 67 | 0.040 |
Why?
| | Feedback | 1 | 2021 | 162 | 0.040 |
Why?
| | Pulmonary Circulation | 1 | 2023 | 431 | 0.040 |
Why?
| | Ventricular Function, Right | 1 | 2023 | 276 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2021 | 148 | 0.040 |
Why?
| | Myocytes, Cardiac | 1 | 2024 | 499 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2020 | 251 | 0.040 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 33 | 0.040 |
Why?
| | Peptide Fragments | 2 | 2015 | 693 | 0.040 |
Why?
| | United States | 4 | 2019 | 13871 | 0.040 |
Why?
| | DNA Topoisomerases, Type II | 1 | 2019 | 43 | 0.040 |
Why?
| | Immunocompromised Host | 1 | 2021 | 199 | 0.040 |
Why?
| | Exercise Therapy | 1 | 2023 | 412 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2014 | 1499 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2022 | 300 | 0.040 |
Why?
| | Societies | 1 | 2018 | 39 | 0.040 |
Why?
| | Logistic Models | 2 | 2015 | 1986 | 0.040 |
Why?
| | Hemangiosarcoma | 1 | 2018 | 21 | 0.040 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2018 | 87 | 0.040 |
Why?
| | DNA Damage | 1 | 2020 | 384 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2022 | 708 | 0.040 |
Why?
| | Arterial Occlusive Diseases | 1 | 2018 | 80 | 0.030 |
Why?
| | Reference Values | 1 | 2018 | 794 | 0.030 |
Why?
| | Phosphorylation | 1 | 2021 | 1713 | 0.030 |
Why?
| | Program Development | 1 | 2019 | 355 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2024 | 2060 | 0.030 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1501 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 391 | 0.030 |
Why?
| | Interprofessional Relations | 1 | 2019 | 277 | 0.030 |
Why?
| | Prospective Studies | 2 | 2022 | 7135 | 0.030 |
Why?
| | Morbidity | 1 | 2017 | 302 | 0.030 |
Why?
| | Mice | 2 | 2023 | 16961 | 0.030 |
Why?
| | Cytokines | 1 | 2023 | 2021 | 0.030 |
Why?
| | Galectin 3 | 1 | 2015 | 20 | 0.030 |
Why?
| | Mitochondria | 1 | 2021 | 876 | 0.030 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2015 | 40 | 0.030 |
Why?
| | Recurrence | 1 | 2018 | 1011 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2015 | 71 | 0.030 |
Why?
| | Program Evaluation | 1 | 2019 | 875 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1088 | 0.030 |
Why?
| | Secondary Prevention | 1 | 2016 | 219 | 0.030 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2014 | 24 | 0.030 |
Why?
| | Intraoperative Care | 1 | 2014 | 46 | 0.030 |
Why?
| | Diastole | 1 | 2015 | 148 | 0.030 |
Why?
| | Breast | 1 | 2015 | 153 | 0.030 |
Why?
| | Global Health | 1 | 2017 | 328 | 0.030 |
Why?
| | SEER Program | 1 | 2015 | 202 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2020 | 1266 | 0.030 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2014 | 51 | 0.030 |
Why?
| | Ohio | 1 | 2014 | 152 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2015 | 215 | 0.030 |
Why?
| | Europe | 1 | 2014 | 363 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 1005 | 0.030 |
Why?
| | Acute Disease | 1 | 2016 | 979 | 0.030 |
Why?
| | Amyloid | 1 | 2014 | 85 | 0.030 |
Why?
| | Phenotype | 1 | 2021 | 3075 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2015 | 400 | 0.030 |
Why?
| | Time Factors | 2 | 2013 | 6555 | 0.020 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2012 | 26 | 0.020 |
Why?
| | Anesthesia | 1 | 2014 | 134 | 0.020 |
Why?
| | Radiology | 1 | 2014 | 159 | 0.020 |
Why?
| | Odds Ratio | 1 | 2015 | 1019 | 0.020 |
Why?
| | Disease Management | 1 | 2016 | 588 | 0.020 |
Why?
| | Action Potentials | 1 | 2015 | 485 | 0.020 |
Why?
| | Consensus | 1 | 2014 | 618 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 851 | 0.020 |
Why?
| | North America | 1 | 2012 | 292 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2015 | 1282 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 515 | 0.020 |
Why?
| | Age Factors | 1 | 2018 | 3152 | 0.020 |
Why?
| | Pilot Projects | 1 | 2016 | 1592 | 0.020 |
Why?
| | Myocardial Contraction | 1 | 2012 | 335 | 0.020 |
Why?
| | Societies, Medical | 1 | 2014 | 744 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 2012 | 381 | 0.020 |
Why?
| | Patient Selection | 1 | 2014 | 661 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2015 | 2720 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3394 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 5075 | 0.010 |
Why?
| | Cohort Studies | 1 | 2013 | 5426 | 0.010 |
Why?
| | Mitral Valve | 1 | 2001 | 85 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2001 | 317 | 0.010 |
Why?
| | Observer Variation | 1 | 2001 | 314 | 0.010 |
Why?
| | Probability | 1 | 2001 | 306 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2001 | 2739 | 0.010 |
Why?
|
|
Banchs's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|